OrisDX launches saliva DNA test for oral cancer in dental settings
OrisDX has introduced Oro Lesion, a saliva-based DNA test for oral cavity squamous cell carcinoma that can be used by dental and medical providers in the U.S. The launch adds a patient navigation tool, Oris Bridge, and aims to speed referral and treatment for people with suspicious oral lesions.
Why it matters: - Oral cavity cancer is often found late, when treatment is harder and survival can drop sharply. - OrisDX is trying to move diagnosis earlier by putting a molecular test into the dental setting, where many suspicious lesions are first seen. - The company says the new workflow is designed to reduce delays between a concerning oral exam and specialized care.
What happened: - OrisDX launched Oro Lesion, a noninvasive saliva DNA test for oral cavity squamous cell carcinoma. - The test is available as a Laboratory Developed Test under CMS CLIA certification and CAP accreditation oversight. - OrisDX also introduced Oris Bridge, a patient navigation system that shares results with the prescribing clinician and patient. - The launch was announced in Chicago on Nov. 16, 2026.
The details: - Oro Lesion is the first noninvasive test for oral cavity squamous cell carcinoma that analyzes DNA from a saliva-based sample, the company said. - OrisDX said the test has 94% sensitivity, 98% specificity, a 96% positive predictive value and a 97% negative predictive value. - The test is offered through dental and medical providers for adults over 18 with an indeterminate oral lesion. - Samples can be collected in a clinic or in the privacy of the patient’s home. - A clinician can collect the sample after a conventional oral exam using the Oro Lesion Collection Kit. - The kit can also be mailed directly to a patient’s home. - Patients return the saliva sample to the OrisDX lab in a prepaid mailer. - The lab uses an automated system to produce a single result: detected or not detected for biomarkers associated with OCSCC. - Results can come back in as little as two weeks. - If the test is positive, the patient navigation system supports the patient’s path to a surgeon. - OrisDX says no special experience is needed to collect the sample. - Head and neck cancer is the sixth most common cancer globally. - Late-stage diagnosis can leave patients with 5-year survival rates as low as 25%. - OrisDX estimates that 1.6 million to 4.9 million adults over 18 are seen by a dentist with an oral lesion that may be cancerous. - If detected earlier, the lesion can be removed and survival can be as high as 90%.
Between the lines: - The launch is aimed at closing a long gap between routine dental care and oncology workups. - The test shifts part of the cancer screening workflow into a setting patients already use for oral health checks. - That could matter most for people whose lesions are suspicious but not yet clearly diagnosed. - The company is also positioning navigation, not just testing, as part of the product.
What's next: - OrisDX plans to add HPV biomarkers to the test for multicancer detection, typically found in the oropharynx. - Oro Lesion is available to patients in the U.S. through healthcare providers. - More information is available at the company’s product page or by calling 1-464-888-3940. - The technology was licensed from the University of Chicago Polsky Center, and the university and Dr. Nishant Agrawal share in equity and royalties under the agreement.
The bottom line: - OrisDX is betting that saliva-based molecular testing, paired with patient navigation, can make oral cancer detection faster, simpler and less fragmented.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
Illinois Tech Journal
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.